Cannabinoids are found in the marijuana plant (cannabis sativa) and are said to be effective in pain management from pain symptoms such as multiple sclerosis, diabetic neuropathy, peripheral neuropathy and nausea and vomiting. A cannabinoid is one of a great collection of complex chemical compounds that naturally occur in the body and operates on major cannabinoid receptors in cells that mediates neurotransmitter release in the brain.
Cannabinoids for these receptors include the endocannabinoid system, that is produced in the body, the phytocannabinoids in cannabis and some other plants, and synthetic cannabinoids. The main cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. Cannabidiol (CBD) is another main constituent of the plant and produces a non-psychotic effect. This paper will look at cannabinoids ability to treat type-2 diabetes.
Here is the full scientific article if you wish to download it.
Type-2 diabetes is firmly associated with abdominal obesity and is normally related to other cardiometabolic risk factors, concluding in a risk of massive cardiovascular disease. Numerous animal and human views indicate that the endocannabinoid network is overactive in the existence of abdominal obesity and/or diabetes. Both central and peripheral endocannabinoid mechanisms, by way of the triggering of cannabinoid 1 receptors, advertise weight growth and related metabolic alterations.
Rimonabant, the first specific cannabinoid 1 receptor blocker in clinical application, has been displayed to decrease body weight, waist circumference, triglycerides, blood pressure, insulin fight index and C-reactive protein rates, and to up the ante in high-density lipoprotein (HDL) cholesterol and adiponectin potencies in both non-diabetic and diabetic overweight/obese subjects.
A 0.5-0.7% decrease in HbA1c levels was seen in metformin- or sulphonylurea-treated people baring type-2 diabetes and in drugnaïve diabetic people. Nearly half of the metabolic alterations, including HbA1c reduction, could not be described by weight reductions, indicating that there are direct peripheral impacts. Rimonabant was normally well put up with, and the security face was parallel in diabetic and non-diabetic subjects, with a greater probability of depressed mood syndromes, nausea and dizziness. Overall, the plausible role of rimonabant in overweight/obese people with type-2 diabetes and at high danger of cardiovascular disease needs more care.
The findings of the endocannabinoid network speak for an indication not only in neuroscience but also in metabolic studies. The taking advantage of its several physiological abilities is a potentially good path for therapeutic uses. Results indicate that cannabinoid 1 receptor blockade is a novel therapeutic plan that addresses the underlying actions of both abdominal obesity and cardiometabolic danger, both being potently related to type-2 diabetes.
Even if lifestyle interference is necessary, the possible job of rimonabant in overweight/obese people with type 2 diabetes and a high danger of cardiovascular disease requires a careful look. The data received in this study demonstrate the therapeutic value of the CB1-receptor antagonist rimonabant 20 mg in people with type-2 diabetes; numerous beneficial impacts hold efficient weight loss, decreased abdominal burden, a clinically massive decrease in HbA1c rates, and improvements in HDL-C, triglycerides, C-reactive protein levels, blood pressure, and insulin resistance. Most metabolic developments- mainly the decreasing in HbA1c and the advancement in HDL-C rates were nearly twice that forecasted from the weight loss alone, consistent with direct peripheral metabolic impacts of the agent.
Security problems primarily concern mild digestive adverse events and mood disorders, which suggest the use of rimonabant in people with a past of depression or on antidepressants. These discoveries indicate the application of rimonabant 20 mg as a new approach to better glucose regulation and decrease multiple cardiovascular and metabolic dangerous factors in overweight/obese people with type-2 diabetes, in relation to diet and exercise, given that psychiatric contraindications are taken care of. Future ongoing research should validate the long-term effectiveness and security of rimonabant, the first specific CB1-receptor antagonist, mainly in people baring type-2 diabetes.